Drug Development
Infigratinib topped “even the most optimistic expectations” for efficacy and safety in the late-stage PROPEL 3 study in achondroplasia, Truist Securities analysts said Thursday.
FEATURED STORIES
Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that there are many more steps before the Alzheimer’s therapy could reach the market.
With a clutch of key data and planned regulatory applications this year from Avidity Biosciences, REGENXBIO and Capricor Therapeutics, CureDuchenne CSO Michael Kelly sees “momentum” in the Duchenne muscular dystrophy pipeline, as Sarepta’s Elevidys leaves the door open.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
The company could lay off as many as 1,000 employees as it continues to deal with the controversial treatment.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Pfizer’s preliminary laboratory studies have shown that the third booster dose increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant.
Several life sciences companies and life science-focused real estate firms have announced expansion plans as 2021 comes to an end.
Neurocrine Biosciences and Acadia Pharmaceuticals posted positive top-line results from their respective Phase III trials on major neurological diseases.
Researchers are working to develop new treatments for Alzheimer’s disease and dementia and improve the already existing ones. Find out more here.
The news comes just three weeks after Merck paused its Phase II IMAGINE-DR trial, which was studying a combination of islatravir with MK-8507.
Despite having 37 new mutations in the viral spike protein, there does not appear to be any deaths associated with Omicron, although it’s spreading rapidly in South Africa.
Ionis will manufacture and supply the drug for ongoing trials and process qualifications, while AstraZeneca will handle the commercial supply of eplontersen.
The WHO’s latest decision is based on advice from an independent panel of experts who evaluated data from 16 randomized controlled studies.